Neuromyelitis Optica Spectrum Disorders

CONTINUUM Lifelong Learning in Neurology

Volumn 22, Issue 3, 2016, Pages 864-896

  Sand, Ilana Katz ^a  

^a Department of Neurology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BACLOFEN; CANNABINOID; CARBAMAZEPINE; CORTICOSTEROID; DULOXETINE; ECULIZUMAB; GABAPENTIN; IMMUNOGLOBULIN; INEBILIZUMAB; MYCOPHENOLATE MOFETIL; OPIATE; PREGABALIN; RITUXIMAB; TIZANIDINE; TOCILIZUMAB; TRICYCLIC ANTIDEPRESSANT AGENT; AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ACUTE DIENCEPHALIC SYNDROME; AREA POSTREMA; AREA POSTREMA SYNDROME; AUTOIMMUNE DISEASE; BRAIN DISEASE; BRAINSTEM SYNDROME; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DIENCEPHALON; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; HICCUP; HUMAN; LABORATORY TEST; LONGITUDINALLY EXTENSIVE TRANSVERSE MYELITIS; MYELITIS; MYELOOPTIC NEUROPATHY; NARCOLEPSY; NAUSEA AND VOMITING; NEUROIMAGING; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PLASMAPHERESIS; REVIEW; SPASTICITY; SYMPTOM; ADULT; BLOOD; CASE REPORT; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; FEMALE; PLASMA EXCHANGE; PROCEDURES;

ADRENAL CORTEX HORMONES; ADULT; AUTOANTIBODIES; CLINICAL TRIALS AS TOPIC; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEUROMYELITIS OPTICA; PLASMA EXCHANGE;

EID: 84974597187     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/CON.0000000000000337     Document Type: Review

References (102)

1. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202(4):473-477. doi:10.1084/jem.20050304.
2. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63(7):964-968. doi:10.1001/archneur.63.7.964.
3. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130(pt 5):1194-1205. doi:10.1093/brain/awl371.
4. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007;69(24): 2221-2231. doi:01.WNL.0000289761.64862.ce.
5. Lim YM, Pyun SY, Lim HT, et al. First-ever optic neuritis: distinguishing subsequent neuromyelitis optica from multiple sclerosis. Neurol Sci 2014;35(5):781-783. doi:10.1007/s10072-014-1635-6.
6. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53(5):1107-1114. doi:10.1212/WNL.53.5.1107.
7. Nakajima H, Hosokawa T, Sugino M, et al. Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC Neurol 2010;10:45. doi:10.1186/1471-2377-10-45.
8. Storoni M, Davagnanam I, Radon M, et al. Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system. J Neuroophthalmol 2013;33(2):123-127. doi:10.1097/WNO.0b013e318283c3ed.
9. Khanna S, Sharma A, Huecker J, et al. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuroophthalmol 2012;32(3):216-220. doi:10.1097/WNO.0b013e318254c62d.
10. Cree BA. Acute inflammatory myelopathies. Handb Clin Neurol 2014;122:613-667. doi:10.1016/B978-0-444-52001-2.00027-3.
11. Bradl M, Kanamori Y, Nakashima I, et al. Pain in neuromyelitis opticaVprevalence, pathogenesis and therapy. Nat Rev Neurol 2014;10(9):529-536. doi:10.1038/nrneurol.2014.129.
12. Elsone L, Townsend T, Mutch K, et al. Neuropathic pruritus (itch) in neuromyelitis optica. Mult Scler 2013;19(4):475-479. doi:10.1177/1352458512457720.
13. Kim SM, Go MJ, Sung JJ, et al. Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics. Arch Neurol 2012;69(8):1026-1031. doi:10.1001/archneurol.2012.112.
14. Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015;84(11):1165-1173. doi:10.1212/WNL.0000000000001367.
15. Lu Z, Qiu W, Zou Y, et al. Characteristic linear lesions and longitudinally extensive spinal cord lesions in Chinese patients with neuromyelitis optica. J Neurol Sci 2010;293(1-2): 92-96. doi:10.1016/j.jns.2010.02.026.
16. Flanagan EP, Weinshenker BG, Krecke KN, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol 2015;72(1):81-87. doi:10.1001/jamaneurol.2014.2137.
17. Nakamura M, Miyazawa I, Fujihara K, et al. Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol 2008;255(2):163-170. doi:10.1007/s00415-008-0545-z.
18. Yokote H, Nose Y, Ishibashi S, et al. Spinal cord ring enhancement in patients with neuromyelitis optica. Acta Neurol Scand 2015;132(1):37-41. doi:10.1111/ane.12354.
19. Misu T, Fujihara K, Nakashima I, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005;65(9):1479-1482. doi:10.1212/01.wnl.0000183151.19351.82.
20. Apiwattanakul M, Popescu BF, Matiello M, et al. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol 2010;68(5):757-761. doi:10.1002/ana.22121.
21. Takahashi T, Miyazawa I, Misu T, et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry 2008;79(9): 1075-1078. doi:10.1136/jnnp.2008.145391.
22. Popescu BF, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 2011;76(14):1229-1237. doi:10.1212/WNL.0b013e318214332c.
23. Kremer L, Mealy M, Jacob A, et al. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler 2014;20(7):843-847. doi:10.1177/1352458513507822.
24. Lana-Peixoto MA, Callegaro D, Talim N, et al. Pathologic yawning in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 2014;3(4):527-532. doi:10.1016/j.msard.2014.04.002.
25. Viegas S, Weir A, Esiri M, et al. Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2009;80(6): 679-682. doi:10.1136/jnnp.2008.157693.
26. Baba T, Nakashima I, Kanbayashi T, et al. Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody. J Neurol 2009;256(2):287-288. doi:10.1007/s00415-009-0139-4.
27. Kume K, Deguchi K, Ikeda K, et al. Neuromyelitis optica spectrum disorder presenting with repeated hypersomnia due to involvement of the hypothalamus and hypothalamus-amygdala linkage. Mult Scler 2015;21(7):960-962. doi:10.1177/1352458515569100.
28. Suzuki K, Nakamura T, Hashimoto K, et al. Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin 4 antibody: a case report and literature review. Arch Neurol 2012;69(10):1355-1359. doi: 10.1001/archneurol.2012.300.
29. Nakano T, Fujimoto T, Fukuda Y, et al. Neuromyelitis optica with syndrome of inappropriate secretion of antidiuretic hormone and hypersomnia associated with bilateral hypothalamic lesions: a case report. Rinsho Shinkeigaku 2011;51(8):599-602. doi:JST.JSTAGE/clinicalneurol/51.599.
30. Yildiz OK, Cevik S, Oztoprak I. Consciousness disturbance and poikilothermia revealing brain involvement in neuromyelitis optica. Acta Neurol Belg 2012;112(2):213-215. doi:10.1007/s13760-012-0029-x.
31. Iorio R, Plantone D, Damato V, Paola Batocchi A. Anorexia heralding the onset of neuromyelitis optica. Intern Med 2013;52(4):489-491. doi:DN/JST.JSTAGE/internalmedicine/52.8992.
32. Nakajima H, Fujiki Y, Ito T, et al. Anti-aquaporin-4 antibody-positive neuromyelitis optica presenting with syndrome of inappropriate antidiuretic hormone secretion as an initial manifestation. Case Rep Neurol 2011;3(3): 263-267. doi:10.1159/000334129.
33. Sekiguchi T, Ishibashi S, Kubodera T, et al. Anhidrosis associated with hypothalamic lesions related to anti-aquaporin 4 autoantibody. J Neurol 2011;258(12): 2293-2295. doi:10.1007/s00415-011-6112-z.
34. Huh SY, Min JH, Kim W, et al. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Mult Scler 2014;20(6):695-704. doi:10.1177/1352458513506953.
35. Magana SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009;72(8):712-717. doi:10.1212/01.wnl.0000343001.36493.ae.
36. Kim W, Kim SH, Lee SH, et al. Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder. Mult Scler 2011;17(9):1107-1112. doi:10.1177/1352458511404917.
37. Clardy SL, Lucchinetti CF, Krecke KN, et al. Hydrocephalus in neuromyelitis optica. Neurology 2014;82(20):1841-1843. doi:10.1212/WNL.0000000000000428.
38. Guo Y, Lennon VA, Popescu BF, et al. Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum. JAMA Neurol 2014;71(8):1025-1029. doi:10.1001/jamaneurol.2014.775.
39. Deguchi S, Deguchi K, Sato K, et al. HyperCKemia related to the initial and recurrent attacks of neuromyelitis optica. Intern Med 2012;51(18):2617-2620. doi:DN/JST.JSTAGE/internalmedicine/51.7898.
40. Suzuki N, Takahashi T, Aoki M, et al. Neuromyelitis optica preceded by hyperCKemia episode. Neurology 2010;74(19):1543-1545. doi:10.1212/WNL.0b013e3181dd445b.
41. Kim W, Park MS, Lee SH, et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler 2010;16(10):1229-1236. doi:10.1177/1352458510376640.
42. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63(3):390-396. doi:10.1001/archneur.63.3.390.
43. Nakamura M, Misu T, Fujihara K, et al. Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler 2009;15(6):695-700. doi:10.1177/1352458509103301.
44. Ito S, Mori M, Makino T, et al. "Cloud-like enhancement" is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol 2009; 66(3):425-428. doi:10.1002/ana.21753.
45. Kim SH, Huh SY, Hyun JW, et al. A longitudinal brain magnetic resonance imaging study of neuromyelitis optica spectrum disorder. PLoS One 2014;9(9): e108320. doi:10.1371/journal.pone.0108320.
46. Banker P, Sonni S, Kister I, et al. Pencil-thin ependymal enhancement in neuromyelitis optica spectrum disorders. Mult Scler 2012;18(7):1050-1053. doi:10.1177/1352458511431730.
47. Makino T, Ito S, Mori M, et al. Diffuse and heterogeneous T2-hyperintense lesions in the splenium are characteristic of neuromyelitis optica. Mult Scler 2013;19(3):308-315. doi:10.1177/1352458512454772.
48. Ruiz-Gaviria R, Baracaldo I, Castañeda C, et al. Specificity and sensitivity of aquaporin 4 antibody detection tests in patients with neuromyelitis optica: a meta-analysis. Mult Scler Relat Disord 2015;4(4):345-349. doi:10.1016/j.msard.2015.06.003.
49. Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 2011;306(1-2):82-90. doi:10.1016/j.jns.2011.03.038.
50. Juryń czyk M, Craner M, Palace J. Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. J Neurol Neurosurg Psychiatry 2015;86(1): 20-25. doi:10.1136/jnnp-2014-308984.
51. Long Y, Qiu W, Lu Z, et al. Aquaporin 4 antibodies in the cerebrospinal fluid are helpful in diagnosing Chinese patients with neuromyelitis optica. Neuroimmunomodulation 2012;19(2): 96-102. doi:10.1159/000330240.
52. Misu T, Takano R, Fujihara K, et al. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 2009;80(5):575-577. doi:10.1136/jnnp.2008.150698.
53. Uzawa A, Mori M, Sawai S, et al. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin Chim Acta 2013;421:181-183. doi:10.1016/j.cca.2013.03.020.
54. Uzawa A, Mori M, Ito M, et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol 2009;256(12):2082-2084. doi:10.1007/s00415-009-5274-4.
55. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66(10):1485-1489. doi:10.1212/01.wnl.0000216139.44259.74.
56. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85(2):177-189. doi:10.1212/WNL.0000000000001729.
57. Petzold A, Wattjes MP, Costello F, et al. The investigation of acute optic neuritis: a review and proposed protocol. Nat Rev Neurol 2014;10(8):447-458. doi:10.1038/nrneurol.2014.108.
58. Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain 2003;126(pt 2): 276-284. doi:10.1093/brain/awg045.
59. Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol 2014;261(1):17-26. doi:10.1007/s00415-013-6957-4.
60. Tobin WO, Weinshenker BG, Lucchinetti CF. Longitudinally extensive transverse myelitis. Curr Opin Neurol 2014;27(3):279-289. doi:10.1097/WCO.0000000000000093.
61. Pekcevik Y, Mitchell CH, Mealy MA, et al. Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging [published online ahead of print July 24, 2015]. Mult Scler. doi:10.1177/1352458515591069.
62. Iyer A, Elsone L, Appleton R, Jacob A. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity 2014;47(3):154-161. doi:10.3109/08916934.2014.883501.
63. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008;65(1): 78-83. doi:10.1001/archneurol.2007.17.
64. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46(6):878-886. doi:10.1002/1531-8249(199912)46:6G878:AID-ANA1093.0.CO;2-Q.
65. Abboud H, Petrak A, Mealy M, et al. Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler 2016;22(2): 185-192. doi:10.1177/1352458515581438.
66. Wingerchuk DM. Neuromyelitis optica: potential roles for intravenous immunoglobulin. J Clin Immunol 2012;33(suppl 1):S33-S37. doi:10.1007/s10875-012-9796-7.
67. Elsone L, Panicker J, Mutch K, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler 2014;20(4): 501-504. doi:10.1177/1352458513495938.
68. Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 2008;122(6): 1238-1239. doi:10.1016/j.jaci.2008.08.033.
69. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998;51(4):1219-1220. doi:10.1212/WNL.51.4.1219.
70. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011;77(7):659-666. doi:10.1212/WNL.0b013e31822a2780.
71. Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, et al. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 2010;67(9):1131-1136. doi:10.1001/archneurol.2010.203.
72. Sahraian MA, Moinfar Z, Khorramnia S, Ebrahim MM. Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients. Eur J Neurol 2010; 17(6):794-799. doi:10.1111/j.1468-1331. 2009.02928.x.
73. Qiu W, Kermode AG, Li R, et al. Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. J Clin Neurosci 2015;22(7): 1178-1182. doi:10.1016/j.jocn.2015.01.028.
74. Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler 2014;20(11):1533-1540. doi:10.1177/1352458514525870.
75. IMURAN (azathioprine). Product Information. www.accessdata.fda.gov/drugsatfda- docs/label/2011/016324s034s035lbl.pdf. Accessed April 3, 2016.
76. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32(5):651-662.
77. Huh SY, Kim SH, Hyun JW, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 2014;71(11):1372-1378. doi:10.1001/jamaneurol.2014.2057.
78. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009;66(9):1128-1133. doi:10.1001/archneurol.2009.175.
79. Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 2014;71(3):324-330. doi:10.1001/jamaneurol.2013.5699.
80. A (mycophenolate mofetil capsules). Product Information. www. accessdata.fda.gov/drugsatfda-docs/label/2009/050722s021, 050723s019, 050758s019, 050759s024lbl.pdf. Accessed April 3, 2016.
81. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64(7):1270-1272. doi:10.1212/01.WNL.0000159399.81861.D5.
82. Kim SH, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011;68(11):1412-1420. doi:10.1001/archneurol.2011.154.
83. Radaelli M, Moiola L, Sangalli F, et al. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients [published online ahead of print July 21, 2015. Mult Scler. doi:10.1177/1352458515594042.
84. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65(11):1443-1448. doi:10.1001/archneur.65.11.noc80069.
85. Bedi GS, Brown AD, Delgado SR, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011;17(10):1225-1230. doi:10.1177/1352458511404586.
86. Kim SH, Huh SY, Lee SJ, et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 2013;70(9):1110-1117. doi:10.1001/jamaneurol.2013.3071.
87. Zéphir H, Bernard-Valnet R, Lebrun C, et al. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol 2015;262(10): 2329-2335. doi:10.1007/s00415-015-7852-y.
88. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350(25): 2572-2581. doi:10.1056/NEJMoa032534.
89. Maloney DG, Grillo-Ló pez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90(6):2188-2195.
90. Yang CS, Yang L, Li T, et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 2013;81(8):710-713. doi:10.1212/WNL.0b013e3182a1aac7.
91. Nakashima I, Takahashi T, Cree BA, et al. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci 2011;18(7):997-998. doi:10.1016/j.jocn.2010.12.011.
92. RITUXAN (rituximab) injection, for intravenous use. Prescribing Information. www.gene.com/download/pdf/rituxan- prescribing.pdf. Accessed April 3, 2016.
93. Jeong IH, Park B, Kim SH, et al. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints [published online ahead of print June 3, 2015]. Mult Scler. doi:10.1177/1352458515587752.
94. Kim SH, Jeong IH, Hyun JW, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol 2015;72(9):989-995. doi:10.1001/jamaneurol.2015.1276.
95. ClinicalTrials.gov. Maintenance Plasma Exchange for Neuromyelitis Optica (MultiPLEX). www.clinicaltrials.gov/ct2/show/NCT01500681. Accessed April 3, 2016.
96. Weinshenker BG, Barron G, Behne JM, et al. Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology 2015;84(17):1805-1815. doi:10.1212/WNL.0000000000001520.
97. Clinicaltrials.gov. Accessed April 3, 2016.
98. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013;12(6):554-562. doi:10.1016/S1474-4422(13)70076-0.
99. Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 2014;82(15):1302-1306. doi:10.1212/WNL.0000000000000317.
100. Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol 2015;72(7):756-763. doi:10.1001/jamaneurol.2015.0533.
101. Coyle PK. Symptom management and lifestyle modifications in multiple sclerosis. Continuum (Minneap Minn) 2016;22(3 Multiple Sclerosis and Other Demyelinating Diseases):815-836.
102. Qian P, Lancia S, Alvarez E, et al. Association of neuromyelitis optica with severe and intractable pain. Arch Neurol 2012;69(11): 1482-1487. doi:10.1001/archneurol.2012.768.